Dyslipidemia: Contemporary Assessment and Management

Conceptual illustration; not a diagnostic image.

Dyslipidemia is one of the most important modifiable determinants of atherosclerotic cardiovascular disease (ASCVD). The clinical objective of lipid management is not simply to normalize a laboratory value, but to reduce lifelong exposure to atherogenic lipoproteins and thereby prevent myocardial infarction, ischemic stroke, peripheral arterial disease, and premature cardiovascular death.

Contemporary management increasingly emphasizes earlier assessment, earlier intervention, lower LDL-C when cardiovascular risk is higher, and sustained treatment over time. The 2026 ACC/AHA guideline represents a major evolution in U.S. practice, incorporating PREVENT risk estimation, absolute LDL-C and non-HDL-C goals, universal adult lipoprotein(a) assessment, selective apolipoprotein B measurement, coronary calcium scoring, and a broader range of non-statin therapies.

Understanding Atherogenic Lipoproteins

LDL cholesterol remains the principal therapeutic lipid target because LDL particles and other apolipoprotein B-containing particles have a causal role in atherosclerosis.

However, LDL-C does not capture every aspect of atherogenic risk. Contemporary assessment may also incorporate non-HDL cholesterol, apolipoprotein B, triglyceride-rich remnants, and lipoprotein(a).

Non-HDL-C represents cholesterol carried by all atherogenic apoB-containing particles and can be particularly informative when triglycerides are elevated.

ApoB reflects the number of circulating atherogenic particles. It may identify residual risk when LDL-C appears satisfactory but particle burden remains high, particularly in patients with diabetes, cardiovascular-kidney-metabolic disease, hypertriglyceridemia, or established cardiovascular disease. The 2026 ACC/AHA guideline specifically supports selective apoB measurement in these settings.

Start With Global Cardiovascular Risk

Lipid treatment should be driven by the patient's overall ASCVD risk rather than an LDL-C concentration in isolation.

The 2026 ACC/AHA guideline replaces the older Pooled Cohort Equations with PREVENT-ASCVD for many adults aged 30–79 years without established ASCVD or subclinical atherosclerosis and with LDL-C between 70 and 189 mg/dL.

Ten-year PREVENT risk is categorized as:

low <3%, borderline 3% to <5%, intermediate 5% to <10%, and high ≥10%.

Thirty-year risk can add important perspective, particularly in younger adults whose short-term risk may appear low despite substantial lifetime exposure to atherogenic lipoproteins.

In European practice, the 2025 ESC/EAS Focused Update uses SCORE2 and SCORE2-OP in appropriate primary-prevention populations and incorporates risk modifiers such as family history, elevated Lp(a), inflammatory disease, obesity, and evidence of subclinical atherosclerosis.

European SCORE2/SCORE2-OP and U.S. PREVENT frameworks use their own categories and eligibility criteria; they should not be interchanged. [1,2]

LDL-C Goals: Risk Determines Intensity

Both contemporary European and American guidance increasingly converge on a principle: the greater the cardiovascular risk, the lower the appropriate LDL-C target.

Within the ESC/EAS framework, LDL-C goals depend on cardiovascular risk: <116 mg/dL (<3.0 mmol/L) for low risk; <100 mg/dL (<2.6 mmol/L) for moderate risk; <70 mg/dL (<1.8 mmol/L) together with a reduction of at least 50% from untreated baseline for high risk; and <55 mg/dL (<1.4 mmol/L) together with a reduction of at least 50% for very high risk. Treatment decisions also depend on baseline LDL-C, clinical conditions and shared decision-making. [2]

The 2026 ACC/AHA guideline reintroduced explicit treatment goals. In primary prevention, patients with borderline or intermediate PREVENT risk generally use an LDL-C goal <100 mg/dL, while high-risk patients use <70 mg/dL. In established ASCVD, targets become progressively more intensive, with <55 mg/dL recommended for many very-high-risk patients.

ACC/AHA treatment targets: [1].

These numbers should not be interpreted independently from the magnitude of LDL-C reduction, clinical risk, treatment tolerance, and lifetime exposure.

Lifestyle Remains Foundational

Healthy lifestyle is essential regardless of whether pharmacological treatment is required.

A cardioprotective dietary pattern emphasizes vegetables, fruits, legumes, whole grains, nuts, fish, unsaturated fats, and minimally processed foods while reducing saturated fat, trans fat, excessive refined carbohydrates, and highly processed foods.

Regular physical activity, healthy body weight, tobacco avoidance, adequate sleep, and control of blood pressure and glucose contribute substantially to overall cardiovascular risk reduction.

However, lifestyle should not be presented as a substitute for indicated pharmacological LDL-C lowering in patients at sufficiently high cardiovascular risk.

Importantly, contemporary ESC and ACC/AHA guidance does not recommend dietary supplements or vitamins as a strategy for LDL-C lowering and ASCVD event prevention.

Statins Remain First-Line Therapy

Statins remain the foundation of pharmacological lipid-lowering therapy because they have extensive evidence for reducing ASCVD events and mortality across a broad spectrum of risk.

The statin evidence base and its application to cardiovascular prevention are summarized in the ACC/AHA and ESC/EAS guidelines. [1,2]

Therapy should be selected according to the LDL-C reduction required and the patient's cardiovascular risk.

High-intensity statin treatment is particularly important in secondary prevention, severe hypercholesterolemia, and many high-risk primary-prevention patients.

A reported history of statin-associated symptoms deserves careful evaluation rather than automatic abandonment of statin treatment. Potential contributors such as drug interactions, thyroid disease, intense physical activity, and alternative musculoskeletal disorders should be considered.

Many patients can tolerate a different statin, a lower dose, an alternative dosing strategy, or combination treatment using a lower statin dose with a non-statin agent.

Combination Therapy: Treat to Goal

Contemporary lipid management increasingly favors combination therapy when statin monotherapy is unlikely to achieve the required LDL-C reduction.

Ezetimibe is frequently the first additional agent because it is oral, generally well tolerated, and provides additional LDL-C reduction when added to statin therapy.

LDL-C lowering and cardiovascular outcome evidence should be distinguished; guideline recommendations summarize the evidence supporting ezetimibe in appropriate populations. [1,2]

In patients requiring substantially greater reduction, a PCSK9 monoclonal antibody such as evolocumab or alirocumab can produce profound LDL-C lowering. Major outcomes trials demonstrated cardiovascular event reduction with these therapies in patients with established ASCVD.

Cardiovascular outcomes evidence for evolocumab comes from FOURIER [4] and for alirocumab from ODYSSEY OUTCOMES [5]. These findings should not automatically be transferred to inclisiran.

This is particularly relevant in patients with very-high-risk ASCVD, familial hypercholesterolemia, or persistently elevated LDL-C despite maximally tolerated conventional therapy.

Bempedoic Acid

Bempedoic acid has become an increasingly important option in contemporary lipid management.

The CLEAR Outcomes trial demonstrated cardiovascular benefit in statin-intolerant patients with or at high risk for cardiovascular disease. This evidence led the 2025 ESC/EAS update to recommend bempedoic acid for patients unable to take statins to achieve their LDL-C goal and to consider its addition in selected high- or very-high-risk patients who remain above target despite maximally tolerated therapy.

Clinical outcomes evidence: CLEAR Outcomes [6].

The 2026 ACC/AHA guideline also incorporates bempedoic acid among evidence-based non-statin treatment options.

Inclisiran

Inclisiran is a small-interfering RNA therapy that reduces hepatic PCSK9 synthesis and produces sustained LDL-C reduction with infrequent maintenance dosing.

Its dosing schedule may offer practical advantages for selected patients in whom adherence to frequent treatment is problematic.

However, an important distinction remains: although its LDL-C-lowering efficacy is established, large cardiovascular outcome trials are still determining whether this translates into the same level of event-reduction evidence already demonstrated with statins, ezetimibe, PCSK9 monoclonal antibodies, and bempedoic acid.

The 2026 ACC/AHA guideline therefore incorporates inclisiran as an LDL-C-lowering option while acknowledging that cardiovascular outcomes data remain under investigation.

LDL-C lowering is not itself proof of cardiovascular event reduction for an individual treatment. [1,2]

Lipoprotein(a): Measure It At Least Once

Lipoprotein(a), or Lp(a), is predominantly genetically determined and is independently associated with ASCVD and calcific aortic valve disease.

Both current European and American guidance now emphasize measuring Lp(a) at least once during adulthood.

The 2025 ESC/EAS update uses Lp(a) thresholds above 50 mg/dL or 105 nmol/L as cardiovascular risk modifiers within its framework. The 2026 ACC/AHA framework uses thresholds of 50 mg/dL or 125 nmol/L. These are guideline-specific thresholds, not fixed conversions between units. [1,2]

Lp(a) should be interpreted in the units reported by the laboratory. Mass concentration in mg/dL and particle concentration in nmol/L cannot be reliably interconverted using a fixed factor because apo(a) isoform size varies. Guideline thresholds should therefore be applied in the reported units and within the relevant guideline framework. Cardiovascular risk increases continuously with Lp(a), rather than beginning abruptly at a single threshold. [3]

Lp(a) concentrations are relatively stable throughout life, so repeated measurement is usually unnecessary unless a specific clinical circumstance or therapy warrants reassessment.

At present, the practical consequence of elevated Lp(a) is primarily to recognize higher cardiovascular risk and intensify control of modifiable factors—particularly LDL-C, blood pressure, smoking, diabetes, and lifestyle.

Specific Lp(a)-lowering therapies remain an active area of clinical investigation.

Emerging evidence: Lp(a)HORIZON

On September 4, 2026, the sponsor reported that the phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular endpoint despite lowering Lp(a). This was a sponsor-reported topline announcement, rather than a full peer-reviewed results publication. It should not be interpreted as proof that all Lp(a)-targeted treatments are ineffective or as a reason to discontinue established cardiovascular prevention.

Preliminary sponsor communication filed with the SEC—not a clinical guideline or peer-reviewed trial results publication. [7]

ApoB and Residual Atherogenic Risk

ApoB can provide clinically useful information when conventional cholesterol measurements may underestimate atherogenic particle burden.

This situation is especially relevant in insulin resistance, metabolic syndrome, diabetes, obesity, chronic kidney disease, and hypertriglyceridemia.

When LDL-C, non-HDL-C, and apoB are discordant, apoB can help identify patients who continue to carry a large number of atherogenic particles despite an apparently acceptable LDL-C concentration.

The 2026 ACC/AHA guideline supports apoB measurement selectively to refine residual risk and treatment decisions, rather than requiring it universally in every patient.

Coronary Artery Calcium Can Refine Uncertain Decisions

Coronary artery calcium (CAC) scoring has an expanded role in the 2026 U.S. guideline.

In selected adults with borderline or intermediate predicted risk where the decision to initiate or intensify lipid-lowering therapy remains uncertain, CAC provides a direct measure of subclinical coronary atherosclerosis.

A CAC score of zero can support deferring pharmacological therapy in carefully selected lower-risk individuals without overriding high-risk conditions. Conversely, increasing CAC burden supports progressively more intensive LDL-C lowering.

The new guideline links increasing CAC burden to progressively lower LDL-C goals, with very extensive calcification approaching secondary-prevention levels of intensity.

European guidance similarly recognizes subclinical coronary atherosclerosis and increased CAC as cardiovascular risk modifiers.

Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) should be considered when LDL-C is markedly elevated, particularly when accompanied by premature ASCVD or a strong family history.

An untreated LDL-C ≥190 mg/dL should prompt evaluation for severe primary hypercholesterolemia and possible FH rather than relying solely on calculated short-term cardiovascular risk.

Because lifelong exposure begins at birth, treatment should begin early and frequently requires combination lipid-lowering therapy.

Identification of an index patient should also prompt consideration of cascade screening of first-degree relatives.

Patients with heterozygous or homozygous FH may require statins, ezetimibe, PCSK9-directed therapy, and—in highly selected severe cases—specialist therapies such as evinacumab or other advanced approaches. The 2026 ACC/AHA guideline explicitly addresses these conditions within its contemporary treatment framework.

Hypertriglyceridemia

Elevated triglycerides are associated with metabolic disease and residual cardiovascular risk, but management depends heavily on the clinical context and degree of elevation.

Lifestyle intervention, weight management, glycemic control, reduction of excessive alcohol intake, identification of secondary causes, and statin therapy remain foundational.

For high- or very-high-risk patients with fasting triglycerides approximately 135–499 mg/dL despite statin therapy, the 2025 ESC/EAS update supports consideration of high-dose icosapent ethyl in appropriate patients.

Severe hypertriglyceridemia requires particular attention because the clinical priority may shift from ASCVD prevention toward prevention of acute pancreatitis.

Rare genetic disorders such as familial chylomicronemia syndrome require specialist evaluation and may now have targeted therapeutic options.

Acute Coronary Syndrome: Intensify Early

The period immediately after an acute coronary syndrome represents an exceptionally high-risk phase.

The 2025 ESC/EAS update specifically emphasizes intensifying lipid-lowering treatment during the index hospitalization, rather than waiting weeks or months after discharge.

For lipid-lowering–naïve patients with ACS who are unlikely to reach their LDL-C goal with statin monotherapy, initiating high-intensity statin plus ezetimibe during hospitalization should be considered.

For patients already receiving lipid-lowering therapy before ACS, treatment should be appropriately intensified according to the additional LDL-C reduction required.

This approach reflects an increasingly important principle in preventive cardiology: when cardiovascular risk is extreme, therapeutic delay has clinical consequences.

Monitoring Treatment

After initiating or changing lipid-lowering therapy, response and adherence should be reassessed rather than assuming treatment has achieved its objective.

The 2026 ACC/AHA framework supports reassessing lipid levels within weeks after initiation or dose adjustment and then periodically once treatment is stable.

Monitoring should include not only LDL-C response but also adherence, tolerability, drug interactions, lifestyle progress, and the emergence of new cardiovascular or metabolic risk factors.

A patient's cardiovascular risk is dynamic, and lipid treatment should evolve accordingly.

Related reading: Cardiovascular Prevention: Contemporary Risk Assessment and Management and Hypertension: Contemporary Assessment and Management.

A Contemporary Perspective

Modern dyslipidemia management is increasingly based on the concept of cumulative exposure to atherogenic particles over time.

The question is no longer simply whether cholesterol is “high” or “normal.”

The clinically relevant questions are: How high is the patient's cardiovascular risk? How much atherogenic lipoprotein exposure has accumulated? What LDL-C level is appropriate for that level of risk? Are additional risk modifiers present? And what combination of therapies can safely achieve and sustain that goal?

The overall direction of contemporary evidence is clear: identify risk earlier, lower atherogenic lipoproteins more effectively when risk is high, and maintain successful treatment over the long term.